Form 4: PMV Pharmaceuticals CEO Exercises Stock Options and Reports Changes in Beneficial Ownership

David Henry Mack, President and CEO of PMV Pharmaceuticals, reports exercising stock options and subsequent changes in beneficial ownership of company stock.

Summary

• David Henry Mack, the President and CEO of PMV Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On December 3, 2024, Mack exercised stock options to acquire 91,750 shares of common stock at a price of $0.53 per share.
• On January 3, 2025, Mack exercised additional stock options to acquire 17,709 shares of common stock at a price of $0.53 per share.
• Following these transactions, Mack directly owns 551,919 shares of PMV Pharmaceuticals common stock.
• Mack also has indirect ownership of 165,307 shares through the Stinson 2021 Irrevocable Trust, 147,915 shares through the Mack/Mulligan 2020 Irrevocable Descendants' Trust, and 56,978 shares through another Mack/Mulligan 2020 Irrevocable Descendants' Trust.
• Mack disclaims beneficial ownership of the shares held in the trusts except to the extent of any pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option exercises. While insider buying can be seen as positive, it's not necessarily a strong indicator without further context.

Positives

• The CEO's exercise of stock options could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the CEO.

Key Dates